Seidman Dominika L, Weber Shannon, Timoney Maria Teresa, Oza Karishma K, Mullins Elizabeth, Cohan Deborah L, Wright Rodney L
Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA; University of California San Francisco School of Medicine, San Francisco, CA.
Family and Community Medicine, University of California San Francisco, San Francisco, CA; HIVE, University of California San Francisco, San Francisco, CA.
Am J Obstet Gynecol. 2016 Nov;215(5):632.e1-632.e7. doi: 10.1016/j.ajog.2016.06.020. Epub 2016 Jul 19.
Pregnancy may increase a woman's susceptibility to HIV. Maternal HIV acquisition during pregnancy and lactation is associated with increased perinatal and lactational HIV transmission. There are no published reports of preexposure prophylaxis use after the first trimester of pregnancy or during lactation.
The purpose of this study was to report the use of preexposure prophylaxis and to identify gaps in HIV prevention services for women who were at substantial risk of HIV preconception and during pregnancy and lactation at 2 United States medical centers.
Chart review was performed on women who were identified as "at significant risk" for HIV acquisition preconception (women desiring pregnancy) and during pregnancy and lactation at 2 medical centers in San Francisco and New York from 2010-2015. Women were referred to specialty clinics for women who were living with or were at substantial risk of HIV.
Twenty-seven women who were identified had a median age of 27 years. One-half of the women had unstable housing, 22% of the women had ongoing intimate partner violence, and 22% of the women had active substance use. Twenty-six women had a male partner living with HIV, and 1 woman had a male partner who had sex with men. Of the partners who were living with HIV, 73% (19/26) were receiving antiretroviral therapy, and 42% (11/26) had documented viral suppression. Thirty-nine percent (10/26) of partners had known detectable virus, and 19% (5/26) had unknown viral loads. Women were identified by clinicians, health educators, and health departments. Approximately one-third of the women were identified preconception (8/27); the majority of the women were identified during pregnancy (18/27) with a median gestational age of 20 weeks (interquartile range, 11-23), and 1 woman was identified in the postpartum period. None of the pregnant referrals had received safer conception counseling to reduce HIV transmission. Twenty-six percent of all women (7/27) were eligible for postexposure prophylaxis at referral, of whom 57% (4/7) were offered postexposure prophylaxis. In 30% (8/27), the last HIV exposure was not assessed and postexposure prophylaxis was not offered. The median time from identification as "at substantial risk" to consultation was 30 days (interquartile range, 2-62). Two women were lost to follow up before consultation. One woman who was identified as "at significant risk" was not referred because of multiple pregnancy complications. She remained in obstetrics care and was HIV-negative at delivery but was lost to follow up until 10 months after delivery when she was diagnosed with HIV. No other seroconversions were identified. Of referrals who presented and were offered preexposure prophylaxis, 67% women (16/24) chose to take it, which was relatively consistent whether the women were preconception (5/8), pregnant (10/15), or after delivery (1/1). Median length of time on preexposure prophylaxis was 30 weeks (interquartile range, 20-53). One-half of women (10/20) who were in care at delivery did not attend a postpartum visit.
Women at 2 United States centers frequently chose to use preexposure prophylaxis for HIV prevention when it was offered preconception and during pregnancy and lactation. Further research and education are needed to close critical gaps in screening for women who are at risk of HIV for pre- and postexposure prophylaxis eligibility and gaps in care linkage before and during pregnancy and lactation. Postpartum women are particularly vulnerable to loss-to-follow-up and miss opportunities for safe and effective HIV prevention.
怀孕可能会增加女性感染艾滋病毒的易感性。孕期和哺乳期母体感染艾滋病毒与围产期和哺乳期艾滋病毒传播增加有关。目前尚无关于怀孕头三个月后或哺乳期使用暴露前预防的报道。
本研究的目的是报告暴露前预防的使用情况,并确定美国两家医疗中心在孕前、孕期和哺乳期有较高艾滋病毒感染风险的女性在艾滋病毒预防服务方面存在的差距。
对2010年至2015年在旧金山和纽约的两家医疗中心被确定为孕前(希望怀孕的女性)、孕期和哺乳期“有重大感染风险”的女性进行病历审查。这些女性被转诊至为感染艾滋病毒或有较高感染风险的女性设立的专科诊所。
确定的27名女性的中位年龄为27岁。一半的女性住房不稳定,22%的女性遭受持续的亲密伴侣暴力,22%的女性有活跃的药物使用情况。26名女性的男性伴侣感染艾滋病毒,1名女性的男性伴侣与男性发生性行为。在感染艾滋病毒的伴侣中,73%(19/26)正在接受抗逆转录病毒治疗,42%(11/26)有病毒抑制的记录。39%(10/26)的伴侣已知病毒可检测,19%(5/26)的病毒载量未知。这些女性由临床医生、健康教育工作者和卫生部门确定。大约三分之一的女性在孕前被确定(8/27);大多数女性在孕期被确定(18/27),中位孕周为20周(四分位间距,11 - 23),1名女性在产后被确定。所有怀孕转诊的女性均未接受过降低艾滋病毒传播的安全受孕咨询。所有女性中有26%(7/27)在转诊时符合暴露后预防的条件,其中57%(4/7)接受了暴露后预防。在30%(8/27)的病例中,未评估最后一次艾滋病毒暴露情况,也未提供暴露后预防。从被确定为“有重大风险”到咨询的中位时间为30天(四分位间距,2 - 62)。两名女性在咨询前失访。一名被确定为“有重大风险”的女性因多种妊娠并发症未被转诊。她继续接受产科护理,分娩时艾滋病毒检测为阴性,但失访至产后10个月,此时她被诊断出感染艾滋病毒。未发现其他血清转化情况。在接受并被提供暴露前预防的转诊女性中,67%(16/24)选择服用,无论女性是孕前(5/8)、孕期(10/15)还是产后(1/1),这一比例相对一致。暴露前预防的中位使用时间为30周(四分位间距,20 - 53)。分娩时接受护理的女性中有一半(10/20)未参加产后随访。
美国两家医疗中心的女性在孕前、孕期和哺乳期被提供暴露前预防时,经常选择使用其预防艾滋病毒。需要进一步研究和教育,以填补在筛查有艾滋病毒感染风险的女性是否符合暴露前和暴露后预防条件方面的关键差距,以及在孕期和哺乳期前后护理联系方面的差距。产后女性尤其容易失访,错过安全有效的艾滋病毒预防机会。